Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002

Sawabata, Noriyoshi; Asamura, Hisao; Goya, Tomoyuki; Mori, Masaki; Nakanishi, Yoichi; Eguchi, Katsumi; Koshiishi, Yoshihiko; Okumura, Meinoshin; Miyaoka, Etsuo; Fujii, Yoshitaka

doi:10.1097/jto.0b013e3181e452b9

Cited by 107 publications

(88 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to previous reports, the 5-year survival rate of clinical stage IV NSCLC is 2-5.8% (21,22). Although the difference between these and the present study may reflect the relatively small sample size of the latter, we argue that even for patients with stage IV NSCLC complete resection of the primary lesion may improve prognosis, attributed, in part, to the implicit selection bias.…”

Section: Discussioncontrasting

confidence: 52%

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Background:The standard treatment for patients with stage IV non-small cell lung cancer (NSCLC) is systemic chemotherapy. However, certain patients, such as those with oligometastasis or M1a disease undergo resection of the primary lesion. Results: The median follow-up duration for the 38 patients (27 men) was 17.7 months (range, 1-82.3 months). The T factors were T1/T2/T3/T4 in 4/16/12/6 patients, respectively. The N factors were N0/N1/N2/N3 in 16/8/12/2 patients, respectively. The M factors were M1a/M1b/M1c in 19/13/6 patients, respectively. Of the 19 M1a patients, 11 were classified as cM0. We introduced the novel classification M-better/M-worse. M-better includes cM0 patients and M1b and M1c patients in whom all lesions have been locally controlled. M-worse includes cM1a patients and M1b and M1c patients in whom lesions cannot be locally controlled. The new M-better/M-worse statuses were 24/14 patients, respectively. The histology of NSCLC was adenocarcinoma/squamous cell carcinoma/others in 30/5/3 patients, respectively. The 5-year overall survival rate was 29%, and the median survival time was 725 days. Squamous cell carcinoma and M-worse were significant factors predicting poor outcomes (P=0.0017, P=0.0007, respectively).Conclusions: Even for stage IV NSCLC patients, resection of the primary lesion may be beneficial, especially for those with M-better status and those not diagnosed with squamous-cell carcinoma (SCC).

show abstract

Section: Discussioncontrasting

confidence: 52%

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…1 Molecular subclassification of tumors is particularly important for such cases because genetic change is the major determinant of the effectiveness of targeted molecular therapy. For example, lung cancers with anaplastic lymphoma kinase (ALK) gene rearrangements are susceptible to treatment with ALK inhibitors (for example, crizotinib), 2 and those with a mutation in the gene encoding epidermal growth factor receptor (EGFR) respond to EGFR inhibitors (for example, erlotinib and gefitinib).…”

mentioning

confidence: 99%

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers

et al. 2014

Self Cite

View full text Add to dashboard Cite

The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of lung cancers has raised significant clinical interest because small molecule inhibitors may be effective to these tumors. As lung cancers with ROS1 rearrangements comprise only 1-3% of lung adenocarcinomas, patients with such tumors must be identified to gain optimal benefit from molecular therapy. Recently, immunohistochemical analyses using a novel anti-ROS1 rabbit monoclonal antibody (D4D6) have shown promise for accurate identification of ROS1-rearranged cancers. To validate this finding, we compared the immunostaining results of tissue microarrays (TMAs) containing 17 ROS1-rearranged and 253 ROS1-non-rearranged lung carcinomas. All 17 ROS1-rearranged cancers showed ROS1 immunoreactivity mostly in a diffuse and moderate-to-strong manner with an H-score range of 5-300 (median, 260). In contrast, 69% of ROS1-non-rearranged cancers lacked detectable immunoreactivity, whereas the remaining 31% showed reactivity mainly in a weak or focal manner. The H-score for the entire ROS1-non-rearranged group ranged from 0 to 240 (median, 0). The difference in H-score between the two cohorts was statistically significant, and the H-score cutoff (Z150) allowed optimal discrimination (94% sensitivity and 98% specificity). Similar but slightly less-specific performance was achieved using the extent of diffuse (Z75%) staining or Z2 þ staining intensity as cutoffs. CD74-ROS1 and EZR-ROS1 fusions were significantly associated with at least focal globular immunoreactivity and plasma membranous accentuation, respectively, and these patterns were specific to ROS1-rearranged cases. Although full-length ROS1 is expressed in some ROS1-non-rearranged cases, we showed that establishment of an optimal set of interpretative criteria makes ROS1 immunohistochemistry a valuable method to rapidly and accurately screen lung cancer patients for appropriate molecular therapy.

show abstract

“…For stage I NSCLC patients, the 5-year survival rate is 79%, which means that up to 20% of patients will experience distant or local recurrence (Sawabata et al, 2010). This indicates that there are unknown poor prognostic factors in early stage NSCLC that result in unfortunate outcomes for patients.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Ma¹,

Chu²,

Liu³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage I non-small cell lung cancer (NSCLC) patients. From January 2004 to December 2007, LVI was detected in 57 patients with T1N0M0 NSCLC; therefore, 114 patients with the same pathology, T stage, and surgery method, but without LVI, were selected as the control group to compare survival. The overall survival and relapse-free survival rates were estimated using the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. The average follow-up length was 59.94 ± 23.1 months. The 5-year overall survival rates of the LVI-negative and the LVI-positive groups were 90.54 and 70.1%, respectively (P = 0.002). A multivariate analysis revealed LVI to be an independent predictive factor (hazard ratio = 4.562; P = 0.004). The 5-year overall survival rates for patients who received postoperative adjunctive therapy and those who did not in the LVI-positive group were 88.2 and 61.5%, respectively, with a P value less than 0.05 in both univariate and multivariate analyses. LVI is a poor prognostic factor in stage I NSCLC patients; postoperative adjunctive therapy is needed to improve the 1820 K.F. Ma et al.

show abstract

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002

Abstract: Analysis of a large cohort in the Japanese registry study found that stage-specific prognosis was within a range similar to other reports. The data presented should provide an important reference for future clinical trials in Japan.

Cited by 107 publications

References 9 publications

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Contact Info

Product

Resources

About